|
21 Companies |
|
18 Products |
|
18 Products |
|
32 Mechanisms of Action |
|
0 Trials |
|
48 News |
|
- | Trial completion date, Trial primary completion date: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Jan 7, 2019
P=N/A, N=932, Completed, Sponsor: Children's Oncology Group
Trial completion date: Mar 2013 --> Aug 2016 | Trial primary completion date: Mar 2013 --> Aug 2016
- | Trial completion date: Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors (clinicaltrials.gov) - Aug 28, 2018
P2, N=20, Completed, Sponsor: Children's Oncology Group
Trial completion date: Mar 2013 --> Aug 2016 | Trial primary completion date: Mar 2013 --> Aug 2016 Trial completion date: Mar 2012 --> Jun 2018
- | Trial completion: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Aug 7, 2018
P=N/A, N=932, Completed, Sponsor: Children's Oncology Group
Trial completion date: Mar 2012 --> Jun 2018 Recruiting --> Completed
- | Trial completion: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Apr 12, 2018
P=N/A, N=247, Completed, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed Active, not recruiting --> Completed
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial completion, Metastases: Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (clinicaltrials.gov) - Feb 7, 2018
P2, N=9, Completed, Sponsor: Fondazione Michelangelo
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion: Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors (clinicaltrials.gov) - Nov 9, 2017
P2, N=20, Completed, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial completion, IO biomarker: Diagnostic Study of Patients With Stage I Testicular Cancer (clinicaltrials.gov) - Oct 23, 2017
P=N/A, N=76, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Trial primary completion date: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Oct 11, 2016
P=N/A, N=932, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Trial primary completion date: Aug 2016 --> Aug 2018
- Neulasta (pegfilgrastim) / Roche
Trial completion, Trial primary completion date: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Jun 19, 2016
P2, N=60, Completed, Sponsor: Memorial Sloan Kettering Cancer Center
Trial primary completion date: Aug 2016 --> Aug 2018 Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016
- || Trial primary completion date: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Apr 9, 2016
P=N/A, N=932, Recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed | Trial primary completion date: Sep 2016 --> Jun 2016 Trial primary completion date: Nov 2015 --> Aug 2016
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment closed, Enrollment change, Metastases: Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (clinicaltrials.gov) - Apr 8, 2016
P2, N=9, Active, not recruiting, Sponsor: Fondazione Michelangelo
Trial primary completion date: Nov 2015 --> Aug 2016 Recruiting --> Active, not recruiting | N=24 --> 9
- Neulasta (pegfilgrastim) / Roche
Trial primary completion date: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Aug 17, 2015
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Recruiting --> Active, not recruiting | N=24 --> 9 Trial primary completion date: Sep 2015 --> Sep 2016
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Trial primary completion date, Metastases: Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (clinicaltrials.gov) - Aug 13, 2015
P2, N=24, Recruiting, Sponsor: Fondazione Michelangelo
Trial primary completion date: Sep 2015 --> Sep 2016 Trial primary completion date: May 2015 --> Aug 2017
- | NN1213 / Novo Nordisk
Trial completion: Acupuncture in Treating Mucositis-Related Pain Caused by Chemotherapy in Patients Undergoing Stem Cell Transplantation (clinicaltrials.gov) - Apr 28, 2015
P=N/A, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> Aug 2017 Recruiting --> Completed
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Enrollment change, Trial primary completion date: Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer (clinicaltrials.gov) - Dec 6, 2014
P2, N=48, Completed, Sponsor: City of Hope Medical Center
Recruiting --> Completed Active, not recruiting --> Completed | N=12 --> 48 | Trial primary completion date: Dec 2015 --> Dec 2014
- | Trial completion: Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors (clinicaltrials.gov) - Sep 8, 2014
P1, N=0, Completed, Sponsor: Indiana University School of Medicine
Active, not recruiting --> Completed | N=12 --> 48 | Trial primary completion date: Dec 2015 --> Dec 2014 No longer recruiting --> Completed
- Neulasta (pegfilgrastim) / Roche
Trial primary completion date: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Aug 15, 2014
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
No longer recruiting --> Completed Trial primary completion date: Sep 2014 --> Sep 2015
- lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment change: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 3, 2014
P1, N=28, Completed, Sponsor: University of California, San Francisco
Trial primary completion date: Sep 2014 --> Sep 2015 N=15 --> 28
- lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Trial completion, Enrollment change: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jul 3, 2014
P1, N=28, Completed, Sponsor: University of California, San Francisco
N=15 --> 28 Recruiting --> Completed | N=15 --> 28
- Enrollment change: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=249, Active, not recruiting, Sponsor: Gynecologic Oncology Group
Recruiting --> Completed | N=15 --> 28 N=200 --> 249
- Enrollment closed: Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy (clinicaltrials.gov) - Feb 25, 2014
P=N/A, N=249, Active, not recruiting, Sponsor: Gynecologic Oncology Group
N=200 --> 249 Recruiting --> Active, not recruiting
- | Ixempra (ixabepilone) - Otsuka, R / Pharm
Trial completion, Metastases: Ixabepilone in Treating Patients With Advanced Cisplatin-Refractory Germ Cell Tumors (clinicaltrials.gov) - Feb 22, 2014
P2, N=29, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Active, not recruiting No longer recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer (clinicaltrials.gov) - Feb 22, 2014
P=N/A, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
No longer recruiting --> Completed Active, not recruiting --> Completed
- | Synagis (palivizumab) / AbbVie, AstraZeneca, SOBI
Trial completion: Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or Colon (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | amphotericin b liposome / Generic mfg.
Trial completion: Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | captopril / Generic mfg.
Trial completion: Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation (clinicaltrials.gov) - Feb 19, 2014
P3, N=35, Completed, Sponsor: Northwestern University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen, Neumega (oprelvekin) / Astellas
Trial completion: Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | fluconazole oral / Generic mfg., itraconazole / Generic mfg.
Trial completion: Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation (clinicaltrials.gov) - Feb 19, 2014
P3, N=578, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation (clinicaltrials.gov) - Feb 19, 2014
P2, N=30, Completed, Sponsor: Fred Hutchinson Cancer Research Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion: SWOG-9442: Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors (clinicaltrials.gov) - Feb 19, 2014
P3, N=270, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed No longer recruiting --> Completed
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
Enrollment open, Metastases: Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (clinicaltrials.gov) - Jan 2, 2014
P2, N=24, Recruiting, Sponsor: Fondazione Michelangelo
No longer recruiting --> Completed Not yet recruiting --> Recruiting
- ifosfamide / Generic mfg., cisplatin / Generic mfg., paclitaxel / Generic mfg.
Trial completion, Metastases: Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Metastatic Testicular Cancer (clinicaltrials.gov) - Dec 16, 2013
P2, N=25, Completed, Sponsor: Medical Research Council
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Positron Emission Tomography in Detecting Testicle Cancer (clinicaltrials.gov) - Oct 16, 2013
P=N/A, N=0, Completed, Sponsor: Institute of Cancer Research, United Kingdom
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Combination Chemotherapy in Treating Male Patients With Germ Cell Tumors (clinicaltrials.gov) - Aug 22, 2013
P2, N=88, Completed, Sponsor: Medical Research Council
Active, not recruiting --> Completed Recruiting --> Completed
- Neulasta (pegfilgrastim) / Roche
Enrollment closed: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Aug 13, 2013
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Recruiting --> Completed Recruiting --> Active, not recruiting
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Trial completion, Metastases: Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors (clinicaltrials.gov) - Aug 5, 2013
P2, N=20, Completed, Sponsor: Cambridge University Hospitals NHS Foundation Trust
Recruiting --> Active, not recruiting Recruiting --> Completed
- ||| Enrollment open: DNA Analysis in Samples From Younger Patients With Germ Cell Tumors and Their Parents or Siblings (clinicaltrials.gov) - Jun 9, 2013
P=N/A, N=932, Recruiting, Sponsor: Children's Oncology Group
Recruiting --> Completed Active, not recruiting --> Recruiting
- Adcetris (brentuximab vedotin) / Takeda, Pfizer
New P2 trial, Metastases: Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (clinicaltrials.gov) - Apr 19, 2013
P2, N=24, Recruiting, Sponsor: Fondazione Michelangelo
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap, Leukine (sargramostim) / Partner Therap
Trial completion: Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer (clinicaltrials.gov) - Mar 20, 2013
P2, N=40, Completed, Sponsor: Cancer Treatment Centers of America
Active, not recruiting --> Recruiting Active, not recruiting --> Completed
- sunitinib / Generic mfg.
Enrollment change, Metastases: Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment (clinicaltrials.gov) - Mar 7, 2013
P2, N=10, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed N=29 --> 10
- Yervoy (ipilimumab) / BMS
Trial completion, IO biomarker: Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer (clinicaltrials.gov) - Dec 20, 2012
P1, N=21, Completed, Sponsor: National Cancer Institute (NCI)
N=29 --> 10 Suspended --> Completed
- Neulasta (pegfilgrastim) / Roche
Enrollment change: Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors (clinicaltrials.gov) - Dec 2, 2012
P2, N=55, Active, not recruiting, Sponsor: Memorial Sloan-Kettering Cancer Center
Suspended --> Completed N=41 --> 55
- Enrollment change, IO biomarker: Diagnostic Study of Patients With Stage I Testicular Cancer (clinicaltrials.gov) - Nov 29, 2012
P=N/A, N=76, Active, not recruiting, Sponsor: Eastern Cooperative Oncology Group
N=41 --> 55 N=315 --> 76
- lapatinib / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Enrollment open: Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 9, 2012
P1, N=15, Recruiting, Sponsor: University of California, San Francisco
N=315 --> 76 Active, not recruiting --> Recruiting
- | amphotericin b liposome / Generic mfg.
Enrollment change: Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) - Sep 19, 2012
P3, N=115, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Recruiting N=450 --> 115
- | Trial completion: Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Men With Previously Untreated Germ Cell Cancer (clinicaltrials.gov) - Sep 19, 2012
P3, N=222, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
N=450 --> 115 Active, not recruiting --> Completed
- | amphotericin b liposome / Generic mfg.
Trial completion: Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients (clinicaltrials.gov) - Sep 19, 2012
P3, N=115, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Enrollment closed: Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors (clinicaltrials.gov) - Aug 2, 2012
P2, N=20, Active, not recruiting, Sponsor: Children's Oncology Group
Active, not recruiting --> Completed Suspended --> Active, not recruiting
- sabarubicin (MEN10755) / Menarini
Trial completion: MEN-10755 in Treating Patients With Solid Tumors (clinicaltrials.gov) - Jul 9, 2012
P1, N=30, Completed, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Suspended --> Active, not recruiting Active, not recruiting --> Completed